Literature DB >> 31030171

Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.

Fereidoon Daryaee1, Peter J Tonge2.   

Abstract

Pharmacokinetic/pharmacodynamic (PK/PD) models predict the effect time course resulting from a drug dose. In this review, we summarize the development of mechanistic PK/PD models that explicitly integrate the kinetics of drug-target interactions into predictions of drug activity. Such mechanistic models are expected to have several advantages over approaches in which concentration and effect are linked using variations of the Hill equation, and where preclinical data are often used as a starting point for modeling drug activity. Instead, explicit use of the full kinetic scheme for drug binding enables time-dependent changes in target occupancy to be calculated using the kinetics of drug-target interactions and drug PK, providing a more precise picture of target engagement and drug action in the non-equilibrium environment of the human body. The mechanistic PK/PD models also generate target vulnerability functions that link target occupancy and effect, and inform on the sensitivity of a target to engagement by a drug. Key factors such as the rate of target turnover can also be integrated into the modeling which, together with target vulnerability, provide additional information on the PK profile required to achieve the desired pharmacological effect and on the utility of kinetic selectivity in developing drugs for specific targets.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31030171      PMCID: PMC7050630          DOI: 10.1016/j.cbpa.2019.03.008

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  38 in total

1.  Pharmacokinetic-pharmacodynamic modeling: time-dependent protein binding--an alternative interpretation of clockwise and counterclockwise hysteresis.

Authors:  J L Pedraz; B Calvo; J A Smithers; G A Thompson
Journal:  J Pharm Sci       Date:  1992-03       Impact factor: 3.534

2.  Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.

Authors:  Lia C Liefaard; Bart A Ploeger; Carla F M Molthoff; Ronald Boellaard; Adriaan A Lammertsma; Meindert Danhof; Rob A Voskuyl
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 3.  PK/PD modelling and simulations: utility in drug development.

Authors:  Iris Rajman
Journal:  Drug Discov Today       Date:  2008-03-07       Impact factor: 7.851

Review 4.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

5.  The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery.

Authors:  Dong Guo; Laura H Heitman; Adriaan P IJzerman
Journal:  ACS Med Chem Lett       Date:  2016-08-19       Impact factor: 4.345

Review 6.  Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.

Authors:  Hao Lu; James N Iuliano; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2018-07-06       Impact factor: 8.822

7.  Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.

Authors:  Angela Abelö; Björn Holstein; Ulf G Eriksson; Johan Gabrielsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

8.  Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

Authors:  Shinji Yamazaki; Justine L Lam; Helen Y Zou; Hui Wang; Tod Smeal; Paolo Vicini
Journal:  J Pharmacol Exp Ther       Date:  2014-07-29       Impact factor: 4.030

9.  Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.

Authors:  R N Upton; D R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-02

10.  Drug-Target Kinetics in Drug Discovery.

Authors:  Peter J Tonge
Journal:  ACS Chem Neurosci       Date:  2017-07-14       Impact factor: 4.418

View more
  8 in total

1.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

Review 2.  Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

Authors:  Tianjing Ren; Xu Zhu; Natalie M Jusko; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-30       Impact factor: 2.410

3.  Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer's Drug Galantamine.

Authors:  Doriano Lamba; Alessandro Pesaresi
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

4.  Reaction Kinetic Models of Antibiotic Heteroresistance.

Authors:  Antal Martinecz; Fabrizio Clarelli; Sören Abel; Pia Abel Zur Wiesch
Journal:  Int J Mol Sci       Date:  2019-08-15       Impact factor: 5.923

Review 5.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

6.  A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases.

Authors:  Hyo-Jeong Ryu; Won-Ho Kang; Taeheon Kim; Jae Kyoung Kim; Kwang-Hee Shin; Jung-Woo Chae; Hwi-Yeol Yun
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

Review 7.  Recent advances in the development of covalent inhibitors.

Authors:  Hyunsoo Kim; Yoon Soo Hwang; Mingi Kim; Seung Bum Park
Journal:  RSC Med Chem       Date:  2021-05-04

8.  Impact of Target Turnover on the Translation of Drug-Target Residence Time to Time-Dependent Antibacterial Activity.

Authors:  Rajeswari Basu; Nan Wang; Sneha Basak; Fereidoon Daryaee; Mustufa Babar; Eleanor K Allen; Stephen G Walker; John D Haley; Peter J Tonge
Journal:  ACS Infect Dis       Date:  2021-08-06       Impact factor: 5.578

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.